Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer

Oncogene

Volumn 30, Issue 41, 2011, Pages 4231-4242

  Musumeci, M ^a   Coppola, V ^a   Addario, A ^a   Patrizii, M ^a   Maugeri Sacca M ^a   Memeo, L ^b   Colarossi, C ^b   Francescangeli, F ^a   Biffoni, M ^a   Collura, D ^c   Giacobbe, A ^c   D'Urso, L ^c   Falchi, M ^a   Venneri, M A ^a   Muto, G ^c   De Maria, R ^a,b   Bonci, D ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Mediterranean Institute of Oncology   (Italy)

^c S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

cancer progression; microenvironment; miRNA

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MICRORNA; MICRORNA 15A; MICRORNA 16; UNCLASSIFIED DRUG;

ARTICLE; CANCER CONTROL; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROSTATE CANCER; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOWN-REGULATION; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

EID: 80054032535     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.140     Document Type: Article

References (54)

1. Acevedo VD, Ittmann M, Spencer DM. (2009). Paths of FGFR-driven tumorigenesis. Cell Cycle 8: 580-588.
2. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW et al. (2007). Cross-talk between paracrine-acting cytokine and chemo-kine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67: 4244-4253. (Pubitemid 46815071)
3. Aqeilan RI, Calin GA, Croce CM. (2010). miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215-220.
4. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L et al. (2009). miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 5553-5559.
5. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
6. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S et al. (2009). MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res 69: 9090-9095.
7. Bhowmick NA, Neilson EG, Moses HL. (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337. (Pubitemid 39551661)
8. Bonci D, Cittadini A, Latronico MV, Borello U, Aycock JK, Drusco A et al. (2003). Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther 10: 630-636. (Pubitemid 36553608)
9. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277.
10. Calin GA, Croce CM. (2006). MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394. (Pubitemid 44289189)
11. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY, von Eschenbach AC. (1989). Co-inoculation of tumorigenic rat prostate mesenchy-mal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer 43: 1179-1187. (Pubitemid 19158056)
12. Chung LW, Cunha GR. (1983). Stromal-epithelial interactions: II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 4: 503-511. (Pubitemid 14236147)
13. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949. (Pubitemid 41377683)
14. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R et al. (1997). Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 31: 223-233. (Pubitemid 27247313)
15. Cunha GR, Chung LW, Shannon JM, Taguchi O, Fujii H. (1983). Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res 39: 559-598.
16. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al. (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269. (Pubitemid 46486616)
17. Efstathiou E, Logothetis CJ. (2010). A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res 16: 1100-1107.
18. Giri D, Ropiquet F, Ittmann M. (1999). Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071. (Pubitemid 29233220)
19. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD et al. (2001). Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61: 8135-8142. (Pubitemid 33091604)
20. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L et al. (2003). Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 278: 21831-21836. (Pubitemid 36792588)
21. Iliopoulos D, Hirsch HA, Struhl K. (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139: 693-706.
22. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. (2010). Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 21: 26-32.
23. Joyce JA, Pollard JW. (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
24. Kalluri R, Weinberg RA. (2009). The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
25. Kaminski A, Hahne JC, Haddouti el M, Florin A, Wellmann A, Wernert N. (2006). Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Mol Med 18: 941-950.
26. Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H. (2009). The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. RNA 15: 249-254.
27. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. (2010). The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17: 28-40.
28. Konig A, Menzel T, Lynen S, Wrazel L, Rosen A, Al-Katib A et al. (1997). Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11: 258-265. (Pubitemid 27085171)
29. Kwabi-Addo B, Ozen M, Ittmann M. (2004). The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11: 709-724. (Pubitemid 40065546)
30. Lewis BP, Burge CB, Bartel DP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. (Pubitemid 40094598)
31. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. (2003). Prediction of mammalian microRNA targets. Cell 115: 787-798. (Pubitemid 38058492)
32. Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R et al. (1996). Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87: 1056-1063. (Pubitemid 26043533)
33. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK et al. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955-960. (Pubitemid 27209095)
34. Nakamoto T, Chang CS, Li AK, Chodak GW. (1992). Basic fibro-blast growth factor in human prostate cancer cells. Cancer Res 52: 571-577.
35. Navarro A, Diaz T, Gallardo E, Vinolas N, Marrades RM, Gel B et al. (2011). Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol 103: 411-415.
36. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S et al. (2003). Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 63: 5754-5760. (Pubitemid 37187471)
37. Polyak K, Weinberg RA. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
38. Risbridger GP, Taylor RA. (2008). Minireview: regulation of prostatic stem cells by stromal niche in health and disease. Endocrinology 149: 4303-4306.
39. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F et al. (2009). MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113: 6669-6680.
40. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW. (2008). Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 6: 176-183.
41. Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke K et al. (2001). Serum levels of the angiogenic cytokines basic fibro-blast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 66: 83-88. (Pubitemid 32154100)
42. Shin VY, Jin H, Ng EK, Cheng AS, Chong WW, Wong CY et al. (2011). NF-kB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis 32: 240-245.
43. Smith JA, Madden T, Vijjeswarapu M, Newman RA. (2001). Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 62: 469-472. (Pubitemid 32607730)
44. Song S, Wientjes MG, Gan Y, Au JL. (2000). Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 97: 8658-8663. (Pubitemid 30639729)
45. Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
46. Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
47. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA et al. (2010). FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
48. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. (2002). Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912-2923. (Pubitemid 35025739)
49. van Moorselaar RJ, Voest EE. (2002). Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 197: 239-250. (Pubitemid 35304798)
50. Wernert N, Kaminski A, Haddouti el M, Hahne JC. (2007). Tumor-stroma interactions of metastatic prostate cancer cell lines: analyses using microarrays. Methods Mol Biol 382: 223-237.
51. Winter SF, Acevedo VD, Gangula RD, Freeman KW, Spencer DM, Greenberg NM. (2007). Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 26: 4897-4907. (Pubitemid 47172640)
52. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. (1994). Derivation of androgen-independent human LNCaP pro-static cancer cell sublines: role of bone stromal cells. Int J Cancer 57: 406-412. (Pubitemid 24168617)
53. Yang F, Strand DW, Rowley DR. (2008). Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene 27: 450-459.
54. Zhang Y, Song S, Yang F, Au JL, Wientjes MG. (2001). Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 299: 426-433. (Pubitemid 32979652)